Efficacy of medical plants on Vaginitis

Comparing the effect of methanol extract of Myrtus communis and clotrimazole on treatment of vaginal candidiasis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013012312250N1

Enrollment

Registered

2013-03-07

Start date

2006-02-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vulvovaginal candidiasis. Vulvovaginal ulceration and inflammation in diseases classified elsewhere

Interventions

Intervention 1: In intervation gruop:Cream vaginal 1%of Myrtus commuins methanol extract was administered an applicator (5 gr) for five consecutive nights. Intervention 2: in control group: vaginal

Treatment - Drugs

In intervation gruop:Cream vaginal 1%of Myrtus commuins methanol extract was administered an applicator (5 gr) for five consecutive nights

in control group: vaginal cream of clotrimazole1% was administered an applicator (5 gr) for five consecutive nights

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Aged 20-30 years; clinical signs and symptoms of Candida vaginitis, pH vaginal (4-4.5) wet smear and culture positive. Exclusion criteria: Pregnant and lactating women; who have multiple sexual partners; diabetes; women with history of chronic Vulvar vaginal Candidiasis (at least 4 times in one year); use of immunosuppressive drugs; current use of oral combined contraceptive pills (OCPs); use of vaginal or oral anti-fungal in a month later and exposure of other Vaginitis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pruritus. Timepoint: Before treatment , 2 and 8 weeks after treatment. Method of measurement: Vsual Analog Scale for severty symptom.;Vaginal discharge. Timepoint: Before treatment , 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom-wet smear-culture.;Vulvar Erythematic. Timepoint: Before treatment , 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom-wet smear-culture.;Dysuria. Timepoint: Before treatment , 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom.;Vulvar Edema. Timepoint: Beftore treatment , 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom-wet test and cultuer.;Disparonia. Timepoint: Before treatment, 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom.	—

Measure

Time frame

Pruritus. Timepoint: Before treatment , 2 and 8 weeks after treatment. Method of measurement: Vsual Analog Scale for severty symptom.;Vaginal discharge. Timepoint: Before treatment , 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom-wet smear-culture.;Vulvar Erythematic. Timepoint: Before treatment , 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom-wet smear-culture.;Dysuria. Timepoint: Before treatment , 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom.;Vulvar Edema. Timepoint: Beftore treatment , 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom-wet test and cultuer.;Disparonia. Timepoint: Before treatment, 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPoorandokht Afshary

Ahvaz University Medical sciences

f_afshary@yahoo.com+98 61 1336 7544

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026